Alpha Tau selected for Startup Competition at Mixiii Biomed Israel 2017

May 14, 2017

As part of only 10 finalists, Alpha Tau was chosen to participate at the Startup Competition for the upcoming Biomed Conference in Israel, May 23rd, 2017. In addition, Prof. Keisari was invited to orally present the highly potent and conformal Alpha DaRT Treatment for solid cancer tumors. Attending with both local and global major players from the health industry is a great encouragement and opportunity to outline the benefits of the Alpha DaRT Treatment and expand ongoing clinical trials.

 

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Please reload

Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

1/5
Please reload

Archive
Please reload

Categories
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.